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A B S T R A C T
Background: Randomized clinical trials have established the beneﬁts of statin therapy in acute coronary
syndromes (ACS) via their pleiotropic effects.
Aim of the study: This was a 12-week, open-label, multicenter, postmarketing observational study
evaluating the efﬁcacy and safety of rosuvastatin 40 mg/day in very high-risk or high-risk Indian patients
according to NCEP ATP III guidelines.
Methodology: One hundred and sixty two patients (age: 30 to 69 years) with evidence of coronary artery
disease, hospitalized with chest pain with/without electrocardiogram changes and with non-ST segment
elevation ACS and ST segment elevation ACS who received optimal reperfusion therapy were enrolled.
The primary endpoint was the percent change from baseline in low-density lipoprotein cholesterol (LDL-
C) levels at 6 and 12 weeks of treatment. Other lipid parameters, high sensitive C-reactive protein
(hsCRP), glycosylated hemoglobin, and clinical biochemical parameters were also assessed.
Results: At 12 weeks, intensive therapy with rosuvastatin 40 mg/day signiﬁcantly reduced LDL-C
(p < 0.001), total cholesterol (TC) (p < 0.001), triglyceride (p < 0.01), TC/high density lipoprotein
cholesterol (HDL-C) ratio (p < 0.001), non-HDL-C (p < 0.001), LDL-C/HDL-C ratio (p < 0.001), and hsCRP
(p = 0.034) in very high-risk and high–risk patients with ACS. Overall, 54.5% (61/112) patients achieved
LDL-C goal of <70 mg/dL. However, the change in HDL-C and very low density lipoprotein cholesterol
(VLDL-C) were not signiﬁcant. Few adverse events including myalgia were reported during the study.
Conclusion: Results of this study showed that 40 mg dose of rosuvastatin, initiated early and continued
for 12 weeks, was effective in terms of reducing LDL cholesterol and was well tolerated.
 2016 Published by Elsevier B.V. on behalf of Cardiological Society of India. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Acute coronary syndromes (ACS) result from acute obstruction
of a coronary artery and may lead to consequences varying from§ Registration number of clinical trials registry: CTRI/2014/01/004269 [Regis-
tered on: 01/01/2014].
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creativecommons.org/licenses/by-nc-nd/4.0/).unstable angina to sudden death.1 Statins have emerged as the
most effective lipid-lowering agents in preventing cardiovascular
(CV) events in patients with established coronary heart disease
(CHD).2 Evidence accumulated over 20 years shows that statins can
lower the long-term CV risk by reducing elevated low-density
lipoprotein cholesterol (LDL-C), small-dense LDL-C, and C-reactive
protein.2,3
The available evidence supports the beneﬁcial effects of the
regular use of statins in ACS, and highlights association between
early initiation and reductions in recurrent coronary events and India. This is an open access article under the CC BY-NC-ND license (http://
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in prevention of CV events.5 Statins increase the release of
endothelial nitric Oxide (NO) independent of cholesterol levels,
thus increasing the NO production and reversing endothelial
dysfunction.1,2,6 Statins have been shown to modulate several
mechanisms involved in the pathogenesis of ACS, such as
stabilizing plaque and decreasing thrombogenicity and inﬂamma-
tion.1,2
The National Cholesterol Education Program (NCEP) Adult
Treatment Panel (ATP) III guidelines recommend that intensive
statin treatment should be used in patients admitted with ACS. As
per guidelines, setting an ‘optional’ target of LDL-C goal <70 mg/dL
for ‘very high-risk’ patients must be left as a therapeutic option on
the basis of clinical trial evidence, whereas a LDL-C goal of
<100 mg/dL can be retained as a strong recommendation for ‘high-
risk patients’.7 Increasing evidence suggests that early adminis-
tration of high dose statins in patients with ACS, aggressively
lowers LDL-C and decreases morbidity and mortality.8
Randomized clinical trials evaluating statin therapy started
early after ACS onset have clearly shown that administration of
statins have beneﬁcial effect on CV events at 6 months which
persisted for 2 years of follow-up.2 A meta-analysis of statin use in
patients with ACS conﬁrmed the beneﬁts of early high-dose statin
administration in decreasing recurrent myocardial ischemia and
possibly coronary revascularization. A mortality beneﬁt in patients
with ACS was observed over the long term (24 months).9
Additionally PRISM (The Platelet Receptor Inhibition in Ischemic
Syndrome Management) study demonstrated that early with-
drawal of statin treatment shortly after onset of ACS symptoms
increases the risk of cardiac events.6
Intensive lipid-lowering statin regimen during ACS provides
greater protection against death or major CV events, and
rosuvastatin is the most potent statin currently available with
the highest efﬁcacy in decreasing LDL-C compared with other
statins. Several studies have demonstrated the higher lipid-
lowering efﬁcacy of rosuvastatin over other statins. Compared
with other potent statins, rosuvastatin has longer half-life of
20 hours with favorable safety proﬁle in the dose range of 5 to
40 mg.3,10 Rosuvastatin in the dose range of 5 to 40 mg has also
shown reduction in LDL-C levels in range of 38.8–54.7 mg/dL.10
The results from SATURN (Study of Coronary Atheroma by
Intravascular Ultrasound: Effect of Rosuvastatin versus Atorvasta-
tin) showed that change in primary efﬁcacy end point percent
atheroma volume (PAV), was comparable between atorvastatin and
rosuvastatin. However, effect on normalized total atheroma volume
(TAV), a secondary end point, was signiﬁcantly more with
rosuvastatin as compared to atorvastatin.11 The CENTAURUS
(Comparison of the Effects Noted in The ApoB:ApoA-1 ratio Using
Rosuvastatin or Atorvastatin in Patients with Acute Coronary
Syndrome) study demonstrated that rosuvastatin 20 mg produced
similar changes in ApoB:ApoA-1 ratio at 3 months when compared
with atorvastatin 80 mg. The study showed that rosuvastatin 20 mg
is as effective as atorvastatin 80 mg in intensive statin treatment.12
There is dearth of data on effect of high dose rosuvastatin in
Indian ‘high’ risk and ‘very high’ risk patients. This study was
undertaken to explore the efﬁcacy and safety of the intensive dose
of rosuvastatin 40 mg/day, initiated early and continued for
12 weeks, in ‘very high’ or ‘high’ risk Indian patients, identiﬁed
as per NCEP ATP III guidelines.
2. Methods
2.1. Trial design
This was a 12-week, open-label, multicenter study (CTRI/2014/
01/004269) evaluating the efﬁcacy and safety of the intensive doseof rosuvastatin, 40 mg/day, initiated early and continued for 12-
weeks, in a very high risk or high risk Indian patients, according to
NCEP ATP III guidelines. Study was conducted in 12 centers spread
across 6 cities in India.
Enrolled patients were prescribed and advised to self-adminis-
ter commercially available rosuvastatin 40 mg orally once daily
(OD) for the period of 12 weeks as per discretion of treating
physicians. During the 2nd visit (after 6 weeks of treatment) and
3rd visit (after 12 weeks of treatment), patients were evaluated if
he/she could tolerate rosuvastatin 40 mg and assessed history of
myalgia/myopathy with increased creatine phosphokinase (CPK)
enzyme levels. At the end of 12 weeks of treatment with
rosuvastatin 40 mg, all patients were titrated to rosuvastatin
20 mg and continued at the discretion of the investigator. Patients,
whose dose titration to rosuvastatin 20 mg was made at 2nd visit
or 3rd visit, were to continue with the same dosage of rosuvastatin
20 mg at the discretion of the investigator. In addition to
rosuvastatin treatment, patients were advised for therapeutic
lifestyle changes (diet, exercise). All concomitant medications
taken by the patient were noted in the case report form. This study
did not interfere with any therapeutic or diagnostic measures
taken by the treating physicians and patients were recruited
regardless of past or present therapeutic regimens.
The study was conducted in accordance with the principles of
the Declaration of Helsinki and in compliance with Good Clinical
Practice guidelines. Written informed consent was obtained from
all study participants before being examined for eligibility criteria.
The study protocol and the informed consent form were reviewed
and approved by relevant Institutional Review Board before
initiation of study.
2.2. Patients
Men and non-pregnant women aged 30 to 69 years, with
evidence of coronary artery disease, who were hospitalized with
recent chest pain (ischemic symptoms) with or without ECG
changes; or with non-ST segment elevation acute coronary
syndrome (ACS) and ST segment elevation ACS were eligible for
enrollment in study.
Main exclusion criteria were: patients receiving intensive lipid-
lowering therapy of rosuvastatin 40 mg for >3 months before
admission; alanine aminotransferase (ALT) levels >3 upper limit
of normal (ULN); unexplained serum creatine kinase (CK) level
>3 ULN; serum creatinine >2 mg/dL; and history of hypersensi-
tivity to statins.
2.3. Endpoints
The primary endpoint was the percent change from baseline in
LDL-C levels after 6 and 12 weeks of treatment. The secondary
endpoints included the percent change from baseline in total
cholesterol (TC), high-density lipoprotein cholesterol (HDL-C),
triglycerides (TG), non-HDL-C, apolipoprotein A-I (ApoA1-I),
apolipoprotein B (ApoB), LDL-C/HDL-C ratio, TC/HDL-C ratio,
non-HDL-C/HDL-C ratio, and ApoB/ApoA-I ratio, after 6 and
12 weeks of treatment; and the percent change from baseline in
the levels of high sensitive C-reactive protein (hsCRP), an
inﬂammatory marker, after 6 and 12 weeks of treatment. Non-
HDL-C was calculated as total cholesterol from whole plasma
minus HDL cholesterol.
The safety and tolerability of rosuvastatin were assessed by
evaluating the incidence and severity of adverse events (AEs),
serious AEs (SAEs), and abnormal laboratory values through
12 weeks of treatment.
Compliance was assessed; patients were considered non-
compliant if they missed their medication for more than 5 days.
Table 1
Patient characteristics at baseline.
Variable(s) N = 162
Age (years) (mean  SD) 53.7  9.0
Weight (kgs) (mean  SD) 72.8  12.6
ATP risk category, n (%)
Very High-risk 68 (42.0%)
High-risk 94 (58.0%)
Smoking history, n (%)
Smoker 26 (16.0%)
Non-Smoker 132 (81.5%)
Missing Data 04 (2.5%)
Concurrent illness, n (%)
Hypertension 85 (52.5%)
Diabetes 57 (35.2%)
Dyslipidemia 50 (30.9%)
CAF 07 (4.3%)
Peripheral artery disease 02 (1.2%)
Missing 46 (28.4%)
Past history, n (%)
Myocardial infarction 28 (17.3%)
Stable angina 24 (14.8%)
Unstable angina 14 (8.6%)
Heart failure 04 (2.5%)
Atrial ﬁbrillation 01 (0.6%)
Missing 102 (63.0%)
Lipid proﬁle (mg/dL), (mean  SD)
LDL-C (n = 162) 119.3  37.2
HDL-C (n = 162) 38.1  10.1
Total Cholesterol (n = 157) 186.3  50.9
VLDL-C (n = 152) 30.0  14.5
Triglycerides (n = 161) 168.2  106.1
Non-HDL Cholesterol (n = 157) 149.1  46.4
TC-HDL-C ratio (n = 155) 5.1  1.5
LDL-C/HDL-C ratio (n = 156) 3.2  1.2
Inﬂammatory marker, (mean  SD)
hsCRP (n = 115) 6.9  12.0
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Fasting blood samples were collected at baseline, and at 6 and
12 weeks, for lipid proﬁle analysis, hsCRP, HbA1c, and biochemical
parameters (ALT, aspartate aminotransferase (AST), liver enzymes,
CPK, and serum creatinine) at a local laboratory. Estimated
glomerular ﬁltration rate (eGFR) was determined in a post hoc
analysis using the Chronic Kidney Disease Epidemiology Collabo-
ration formula (CKD-EPI).
Safety analysis was performed on safety population, which
consisted of all patients who received at least one dose of the study
medication and had at least one post-baseline safety assessment.
2.5. Statistics
Baseline values were compared with follow-up values using
repeated measures ANOVA and paired t-test. All statistical tests
were two-sided and a ‘p’ value of <0.05 was considered
statistically signiﬁcant.
3. Results
A total of 228 patients were screened and 162 patients (males:
123 [75.9%]; females: 39 [24.1%]) with mean (SD) age of 53.7
(9.0) years, were enrolled in the study. A total of 112 (69.1%)
patients completed the study, 32 (19.8%) patients were lost to follow-
up, and 18 (11.1%) patients were dropped out from the study. Patient
characteristics at baseline are presented in Table 1.
3.1. Efﬁcacy
A repeated measure ANOVA was conducted to compare the
effect of rosuvastatin intensive therapy on lipid levels (Table 2). All
lipid parameters improved signiﬁcantly (p < .001) at week 12. The
result of ANOVA indicated signiﬁcant effect of rosuvastatin therapy
on patients’ LDL levels, Wilks’ Lambda = 0.437, F (2, 93) = 59.86. Of
112 patients who completed the study, overall 88 (78.6%) patients
achieved ATP III LDL-C goal of 100 mg/dL. Out of this 61 (54.5%)
patients achieved LDL-C goal of <70 mg/dL. Follow-up comparison
indicated that each pair wise comparison was signiﬁcant. LDL-C
levels decreased by 46.9 mg/dL (95%CI: 57.3 to 36.5) at week
6 compared to baseline, and by 40.5 mg/dL (95%CI 52.0 to 29.0)
at week 12 compared to baseline. These results suggest that
rosuvastatin therapy resulted in signiﬁcant decrease in LDL levels.
After 12 weeks, rosuvastatin therapy had similar effect on TC,
Wilks’ Lambda = 0.487, F (2,91) = 47.88; triglyceride, Wilks’ Lamb-
da = 0.859, F (2,91) = 7.45; TC/HDL-C ratio, Wilks’ Lambda = 0.529,
F (2,90) = 40.11; non-HDL-C, Wilks’ Lambda = .469, F
(2,90) = 51.11 and LDL-C/HDL-C ratio, Wilks’ Lambda = 0.511, FTable 2
Mean change in lipid levels (mg/dL) after 6 weeks and 12 weeks of treatment compar
Variables N = 228 Baseline Week 6 Difference (9
n Mean  SD Mean  SD 
LDL-C 95 121.1  40.3 74.2  30.8 46.9a (57.
TC 93 189.0  45.2 139.1  39.3 49.9a (62.
Triglyceride 93 166.8  88.0 138.4  55.6 28.4a (48.
HDL-C 94 38.7  10.0 37.8  8.3 0.9 (3.3, 
VLDL-C 90 30.6  14.4 27.5  11.2 3.1 (6.7, 
TC/HDL-C ratio 92 5.1  1.5 3.7  1.1 1.4a (1.7
LDL-C/HDL-C ratio 92 3.2  1.2 2.0  0.9 1.2a (1.4
Note: Based on estimated marginal means.
CI = conﬁdence interval, HDL-C = high-density lipoprotein cholesterol, LDL-C = low-den
C = very low-density lipoprotein cholesterol.
a The mean difference is signiﬁcant at the 0.05 level.
b Adjustment for multiple comparisons: Bonferroni.(2,90) = 43.01 (Table 2). However, rosuvastatin therapy had no
signiﬁcant effect on HDL-C, Wilks’ Lambda = 0.958, F
(2,92) = 2.01 and VLDL-C, Wilks’ Lambda = 0.955, F (2,88) = 2.06. Lipid
levels were also decreased from baseline after dose titration but the
changes were not signiﬁcant. Results for change in lipid levels at
week 6 and week 12 are illustrated in Figs. 1 and 2, respectively.
In addition to this, compared to baseline inﬂammatory marker
hs-CRP decreased by 3.0 (95%CI: 6.2 to 0.2; P > .05) at week 6, and
by 1.4 (95%CI: 2.7 to 0.1; P < .05) at week 12.
3.2. Tolerability
Changes from baseline to the end of treatment for all
biochemical parameters were not signiﬁcant. After 12 weeks of
treatment, CPK levels increased marginally by 0.9 U/L; no patiented to baseline.
5% CI) P value Week 12 Difference (95% CI) P value
Mean  SD
3, 36.5) 0.000 80.6  32.8 40.5a (52.0, 29.0) 0.000
3, 37.4) 0.000 144.8  41.6 44.2a (56.8, 31.5) 0.000
9, 7.8) 0.003 133.6  52.6 33.2a (54.0, 12.3) 0.001
1.4)b 0.926 39.4  9.9 0.7 (1.8, 3.1)b 1.000
0.6) 0.140 28.4  22.0 2.2 (8.4, 4.1) 1.000
, 1.0) 0.000 3.8  1.6 1.3a (1.7, 0.8) 0.000
, 0.8) 0.000 2.4  2.6 0.8a (1.4, 0.1) 0.029
sity lipoprotein cholesterol, SD = standard deviation, TC = total cholesterol, VLDL-
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Fig. 1. Mean change in LDL, TC, TG and non-HDL-C levels at week 6 and week 12.
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Fig. 2. Mean change in HDL-C. VLDL-C, TC-HDL ratio and LDL-HDL ratio at week 6 and week 12.
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signiﬁcantly by 36.5 IU/L (P < 0.01), and SGPT levels were non-
signiﬁcantly reduced by 5.3 IU/L (P > 0.05). Mean serum creatinine
levels at baseline and week 12 remained unchanged. In a post hoc
analysis, the eGFR increase between baseline and week 12 was
minimal and not statistically signiﬁcant. The levels of HbA1c from
baseline to week 12 remained unchanged. Changes in laboratory
values at week 12 from baseline are listed in Table 3.Table 3
Assessment of tolerability parameter.
Variable Mean  SD 
Baseline Week 6 Wee
CPK U/L (n = 87) – 101.7  58.0 102.
SGOT U/L (n = 73) 60.6  98.5 – 24.
SGPT U/L (n = 72) 50.0  37.6 – 44.
Serum creatinine mg/dL (n = 107) 1.0  0.4 – 1.
eGFR (n = 107) 84.6  32.9 – 85.
eGFR using CKD-EPI (n = 107) 84.8  25.3 – 84.
CPK = creatinine phosphokinase, eGFR = estimated glomerular ﬁltration rate, SGOT = serum
a Paired samples t-test.3.3. Safety
A total of 8 (3.5%) AEs were reported by 8 (3.5%) patients.
Myalgia was most commonly reported AE reported by 5 (2.2%)
patients. Adverse events reported were considered to be treatment
related and led to dose titration in all the 8 patients. None of the
AEs were categorized as serious in intensity nor did patient have a
CPK value outside the normal range.Mean change from baseline to week 12 (95%CI) P valuea
k 12
6  67.6 0.9 (8.4, 10.3) >0.05
1  9.0 36.5 (59.2, 13.8) <0.01
7  19.2 5.3 (11.5, 0.9) >0.05
0  0.3 0.0 (0.0, 0.1) >0.05
6  52.4 1.0 (10.0, 12.0) >0.05
9  22.4 0.1 (5.4, 5.6) >0.05
 glutamic oxaloacetic transaminase, SGPT = serum glutamic pyruvic transaminase.
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Statins are the drugs of ﬁrst choice in treating hypercholester-
olemia and have proven beneﬁts on outcomes of CV morbidity and
mortality.10 Large secondary prevention trials have proved the
efﬁcacy of statins in preventing CV morbidity and mortality in
patients with coronary heart disease.4 Evidence from MIRACL and
other studies suggest that statin treatment during ACS has
beneﬁcial effects on risk reduction in both the short term (during
hospitalization) and long term (up to 1 year).4
Statins possesses pleiotropic effects and upregulates the
expression of endothelial NO synthase, thus increasing the NO
production.4 Statins may also repair damaged endothelium by
promoting mobilization of endothelial progenitor cells and
accelerating re-endothelialization of injured vessels.4 Rosuvastatin
has demonstrated established clinical efﬁcacy and safety in treating
dyslipidemia in numerous clinical trials and post marketing
analyses. Prolonged treatment with rosuvastatin is expected to
produce pronounced beneﬁt in patients at high risk of any major
vascular event.3
In this post marketing observational study evaluating the clinical
efﬁcacy and safety of the intensive dose of rosuvastatin 40 mg/day
in patients with ACS, encouraging results have been observed. The
results showed that rosuvastatin signiﬁcantly reduces mean LDL-C
by 46.9 mg/dL (P < 0.001) after 6 weeks of treatment and by
40.5 mg/dL after 12 weeks of treatment. These results are consistent
with previous established clinical studies. Dose ranging studies
have proved that rosuvastatin up to 40 mg dose produces
statistically signiﬁcant dose-dependent decrease in LDL-C by 52–
63% at 6 weeks compared with placebo.13 Another study comparing
different doses of rosuvastatin and atorvastatin showed that
rosuvastatin 10–40 mg reduces LDL-C by 47–57% compared with
38–54% with atorvastatin 10–80 mg.15 Similar results were
obtained with the Statin Therapies for Elevated Lipid Levels
compared Across doses to Rosuvastatin (STELLAR) study in patients
with hypercholesterolemia with rosuvastatin 10–40 mg.13
Acute coronary syndrome signiﬁcantly affects the concentration
and composition of the lipids and lipoproteins in plasma. In the
LUNAR (Limiting UNdertreatment of lipids in ACS with Rosuvas-
tatin) study, the ﬁnding suggests that rosuvastatin 40 mg/day was
signiﬁcantly more effective than atorvastatin 80 mg/day in
decreasing LDL-C and other important lipid parameters, such as
apolipoprotein AI, LDL-C/HDL-C, non-HDL-C/HDL-C, TC/HDL-C, and
apolipoprotein B/apolipoprotein AI, is consistent with previous data
from patients without ACS and with the SATURN study.14
According to the NCEP-ATP III clinical guidelines, therapy is
dependent on the CV risk.10 ‘Very high’ risk occurs in pre-existing
CV episode (myocardial infarction), stable or unstable angina,
coronary artery procedure (angioplasty or bypass), or otherwise
evidence of clinically signiﬁcantl myocardial ischemia involving
more than one risk factor (e.g., diabetes, hypertension, persistent
smoking).7,10 ‘High’ risk occurs in previous coronary disease
conditions or its equivalent (peripheral artery disease, aneurysm of
abdominal aorta, carotid disease (including transient ischemic
attack or apoplexy of carotid origin or >50% obstruction of any
carotid artery) or primary atherogenic dyslipidemia), as well as in
those people which multiple risk factors with >20% risk of 10 years
coronary disease.7,10
The present study ﬁndings indicate signiﬁcant decreases in TC
(P < 0.001), triglyceride (P < 0.01), TC/HDL-C ratio (P < 0.001), and
LDL-C/HDL-C ratio (P < 0.001) which is consistent with the
ﬁndings of LUNAR study. No signiﬁcant changes were observed
in change in lipid levels after dose titration.
Although there is no consensus on the optimal time of
administration of statins during ACS, some clinical trials and
pooled analyses provide substantial support for the institution ofan early therapy to improve strategies that target the pathophysi-
ologic mechanism operating during myocardial infarction. In
particular, recent ﬁndings suggest that the earlier the treatment is
started after the diagnosis of ACS, the greater the expected beneﬁt.
The results of the SATURN study suggest that rosuvastatin may be
preferable in ‘very high’ risk patients with ACS in whom a target
LDL-C <70 mg/dL is desirable.11
In the SATURN study, HDL-C was signiﬁcantly increased with
rosuvastatin 40 mg and persisted over the 12-week study period.11
However, in the present study, HDL-C increased marginally (0.7 mg/
dL) in patients after 12 weeks of rosuvastatin therapy. Changes in
laboratory values of CPK, SGPT, serum creatinine, eGFR, and HbA1c
from baseline to week 12 was not clinically signiﬁcant except for
SGOT which decreased signiﬁcantly by 36.5 IU/L (P < 0.01).
Rosuvastatin is well tolerated with lesser-known adverse
events. Reporting of adverse events could be affected by patient’s
awareness. Myalgia is the commonest side effect with statin
therapy13 and the current study also reﬂects this. None of the AEs
were categorized as serious in intensity. There were no deaths
during the rosuvastatin treatment. These ﬁndings are consistent
with the previous clinical trials with rosuvastatin.13 Rosuvastatin
exhibits a desirable pharmacologic and safety proﬁle.
Recent clinical trials have generated promising results that have
supported the concept of the cardioprotective effect of statin
administration as ﬁrst-line therapy for ACS.2 Patients could receive
a statin as early as possible following ACS.1 Statin therapy should
not be discontinued in unstable patients with ACS as it may revoke
its beneﬁcial effects.6
The limitation of the study is being post marketing observa-
tional study; most of the patients were lost to follow-up, due to
logistical problems, or because patients were unable to follow-up
on time due to their residence in remote areas.
5. Conclusion
The present study evaluated the safety and efﬁcacy of high-
intensity rosuvastatin therapy in Indian ACS patients. It can be
concluded from the results of this study that 40 mg dose of
rosuvastatin, initiated early and continued for 12 weeks, was
effective in terms of reducing LDL cholesterol and was well
tolerated.
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